Cystic fibrosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Race) |
|||
| (27 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} {{AE}} | {{CMG}} {{AE}} {{SHH}} | ||
{{Cystic fibrosis}} | {{Cystic fibrosis}} | ||
==Overview== | ==Overview== | ||
The [[incidence]] of cystic fibrosis is approximately 1 in 2500 livebirths. It is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive. Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients. Although cystic fibrosis has been reported in all racial and [[Ethnic group|ethnic groups]], it mostly affects Caucasians of Northern European descent. It affects men and women equally. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of cystic fibrosis is approximately | *The [[incidence]] of cystic fibrosis is approximately 40 in 100,000 live births worldwide. | ||
*The [[incidence]] of cystic fibrosis is approximately 25 in 100,000 newborns in the US.<ref name="pmid28129811">{{cite journal |vauthors=Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR |title=Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation |journal=J. Pediatr. |volume=181S |issue= |pages=S4–S15.e1 |date=February 2017 |pmid=28129811 |doi=10.1016/j.jpeds.2016.09.064 |url=}}</ref><ref name="pmid12606185">{{cite journal |vauthors=Ratjen F, Döring G |title=Cystic fibrosis |journal=Lancet |volume=361 |issue=9358 |pages=681–9 |year=2003 |pmid=12606185 |doi=10.1016/S0140-6736(03)12567-6 |url=}}</ref> | |||
===Prevalence=== | ===Prevalence=== | ||
* | *Cystic fibrosis affects more than 30,000 people in the United States and 80,000 people worldwide.<ref name="pmid28441669">{{cite journal |vauthors=Brown SD, White R, Tobin P |title=Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment |journal=JAAPA |volume=30 |issue=5 |pages=23–27 |date=May 2017 |pmid=28441669 |doi=10.1097/01.JAA.0000515540.36581.92 |url=}}</ref> | ||
=== | ===Mortality rate=== | ||
* | *Cystic fibrosis is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive.<ref name="pmid25764168">{{cite journal |vauthors=Pittman JE, Ferkol TW |title=The Evolution of Cystic Fibrosis Care |journal=Chest |volume=148 |issue=2 |pages=533–542 |date=August 2015 |pmid=25764168 |pmc=4524331 |doi=10.1378/chest.14-1997 |url=}}</ref> | ||
===Age=== | ===Age=== | ||
* | *Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients.<ref name="pmid20478499">{{cite journal |vauthors=Ernst MM, Johnson MC, Stark LJ |title=Developmental and psychosocial issues in cystic fibrosis |journal=Child Adolesc Psychiatr Clin N Am |volume=19 |issue=2 |pages=263–83, viii |date=April 2010 |pmid=20478499 |pmc=2874200 |doi=10.1016/j.chc.2010.01.004 |url=}}</ref> | ||
===Race=== | ===Race=== | ||
* Although cystic fibrosis has been reported in all racial and [[Ethnic group|ethnic groups]], it mostly affects Caucasians of Northern European descent. | |||
* Cystic fibrosis is the most [[lethal]] [[Genetic disorder|genetic disease]] among Caucasians | |||
* Cystic fibrosis is approximately reported in different [[Ethnic group|ethnic groups]] as follow:<ref name="pmid25083129">{{cite journal |vauthors=Pettit RS, Fellner C |title=CFTR Modulators for the Treatment of Cystic Fibrosis |journal=P T |volume=39 |issue=7 |pages=500–11 |date=July 2014 |pmid=25083129 |pmc=4103577 |doi= |url=}}</ref><ref name="pmid25404111">{{cite journal |vauthors=Cutting GR |title=Cystic fibrosis genetics: from molecular understanding to clinical application |journal=Nat. Rev. Genet. |volume=16 |issue=1 |pages=45–56 |year=2015 |pmid=25404111 |pmc=4364438 |doi=10.1038/nrg3849 |url=}}</ref> | |||
{| | |||
! colspan="2" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|'''Prevalence of cystic fibrosis according to race'''}} | |||
|- | |||
! style="background: #7d7d7d; text-align: center;" + |{{fontcolor|#FFF|'''Race'''}} | |||
! style="background: #7d7d7d; text-align: center;" + |{{fontcolor|#FFF|'''Prevalence (per 100,000 person years)'''}} | |||
|- | |||
| style="background: #DCDCDC; text=align: center;" + |'''Caucasian''' | |||
| style="background: #F5F5F5; text=align: center;" + | 40 | |||
|- | |||
| style="background: #DCDCDC; text=align: center;" + |'''Hispanic''' | |||
| style="background: #F5F5F5; text=align: center;" + | 7.4 | |||
|- | |||
| style="background: #DCDCDC; text=align: center;" + |'''African-American''' | |||
| style="background: #F5F5F5; text=align: center;" + | 6.6 | |||
|} | |||
===Gender=== | ===Gender=== | ||
* | *Cystic fibrosis affects men and women equally. Women with cystic fibrosis have a shortened [[life expectancy]] compared to men.<ref name="pmid25495366">{{cite journal |vauthors=Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R |title=Gender differences in outcomes of patients with cystic fibrosis |journal=J Womens Health (Larchmt) |volume=23 |issue=12 |pages=1012–20 |date=December 2014 |pmid=25495366 |pmc=4442553 |doi=10.1089/jwh.2014.4985 |url=}}</ref> | ||
=== | |||
=== | |||
=== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Latest revision as of 20:34, 29 March 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis epidemiology and demographics |
|
Risk calculators and risk factors for Cystic fibrosis epidemiology and demographics |
Overview
The incidence of cystic fibrosis is approximately 1 in 2500 livebirths. It is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive. Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients. Although cystic fibrosis has been reported in all racial and ethnic groups, it mostly affects Caucasians of Northern European descent. It affects men and women equally.
Epidemiology and Demographics
Incidence
- The incidence of cystic fibrosis is approximately 40 in 100,000 live births worldwide.
- The incidence of cystic fibrosis is approximately 25 in 100,000 newborns in the US.[1][2]
Prevalence
- Cystic fibrosis affects more than 30,000 people in the United States and 80,000 people worldwide.[3]
Mortality rate
- Cystic fibrosis is a life-limiting disease (100% mortality rate), and a cure for the disease remains elusive.[4]
Age
- Most patients with cystic fibrosis are diagnosed in first 2 years of life. The onset of symptoms is before the first month of life in 12%, between 1-6 months of age in 75%, and between 6-12 months of age in 7% of patients.[5]
Race
- Although cystic fibrosis has been reported in all racial and ethnic groups, it mostly affects Caucasians of Northern European descent.
- Cystic fibrosis is the most lethal genetic disease among Caucasians
- Cystic fibrosis is approximately reported in different ethnic groups as follow:[6][7]
| Prevalence of cystic fibrosis according to race | |
|---|---|
| Race | Prevalence (per 100,000 person years) |
| Caucasian | 40 |
| Hispanic | 7.4 |
| African-American | 6.6 |
Gender
- Cystic fibrosis affects men and women equally. Women with cystic fibrosis have a shortened life expectancy compared to men.[8]
References
- ↑ Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR (February 2017). "Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation". J. Pediatr. 181S: S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064. PMID 28129811.
- ↑ Ratjen F, Döring G (2003). "Cystic fibrosis". Lancet. 361 (9358): 681–9. doi:10.1016/S0140-6736(03)12567-6. PMID 12606185.
- ↑ Brown SD, White R, Tobin P (May 2017). "Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment". JAAPA. 30 (5): 23–27. doi:10.1097/01.JAA.0000515540.36581.92. PMID 28441669.
- ↑ Pittman JE, Ferkol TW (August 2015). "The Evolution of Cystic Fibrosis Care". Chest. 148 (2): 533–542. doi:10.1378/chest.14-1997. PMC 4524331. PMID 25764168.
- ↑ Ernst MM, Johnson MC, Stark LJ (April 2010). "Developmental and psychosocial issues in cystic fibrosis". Child Adolesc Psychiatr Clin N Am. 19 (2): 263–83, viii. doi:10.1016/j.chc.2010.01.004. PMC 2874200. PMID 20478499.
- ↑ Pettit RS, Fellner C (July 2014). "CFTR Modulators for the Treatment of Cystic Fibrosis". P T. 39 (7): 500–11. PMC 4103577. PMID 25083129.
- ↑ Cutting GR (2015). "Cystic fibrosis genetics: from molecular understanding to clinical application". Nat. Rev. Genet. 16 (1): 45–56. doi:10.1038/nrg3849. PMC 4364438. PMID 25404111.
- ↑ Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R (December 2014). "Gender differences in outcomes of patients with cystic fibrosis". J Womens Health (Larchmt). 23 (12): 1012–20. doi:10.1089/jwh.2014.4985. PMC 4442553. PMID 25495366.